GlobeNewswire

Basilea receives CHF 5 million milestone payment related to marketing authorization of antifungal Cresemba® in Russia

Share

Basel, Switzerland, June 22, 2020

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has received a CHF 5 million milestone payment from its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”). The milestone was triggered by the granting of the marketing authorization for the antifungal Cresemba® (isavuconazole) in the Russian Federation.

David Veitch, Chief Executive Officer, said: “We are very pleased that physicians in Russia will soon be able to prescribe Cresemba for their patients with invasive mold infections. This approval is an important milestone in the global commercial roll-out of the brand, as Russia is one of the commercially most important markets outside of China, the EU and the U.S.”

In Russia, oral Cresemba is approved in adults for the treatment of invasive aspergillosis and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate.1 The intravenous formulation is currently being reviewed under a separate marketing authorization application.

In June 2017, Basilea entered into a licensing agreement with Pfizer for isavuconazole in Europe (excluding the Nordics), Russia, Turkey and Israel. The agreement was extended in November 2017 to China, including Hong Kong and Macao, and sixteen countries in the Asia-Pacific region. Under the agreement with Pfizer, Basilea is still eligible for regulatory and sales milestone payments of approximately USD 630 million, in addition to receiving mid-teen royalties on in-market sales of Cresemba.

Cresemba is currently marketed in more than 40 countries, including the United States, most EU member states and several additional countries inside and outside of Europe. For the full-year 2019, total "in-market" sales of Cresemba amounted to approximately 200 million U.S. dollars, which is a more than 30 percent growth year-on-year.2

About Cresemba (isavuconazole)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.3 This is also the approved indication for Cresemba in Russia. Cresemba is also approved in the United States and several additional countries in Europe and beyond.4 It has orphan drug designation in the U.S., Europe and Australia for its approved indications. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

References

  1. Ministry of Health of the Russian Federation, June 2020
  2. IQVIA, December 2019. In-market sales reported as moving annual total (MAT) in U.S. Dollar corrected for currency fluctuations.
  3. European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: June 21, 2020]
  4. The registration status and approved indications may vary from country to country.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Workday levererar skräddarsydda upplevelser för anställda med hjälp av lösningar för en arbetsmiljö i förändring2.7.2020 10:00:10 CESTPressemelding

Workday erbjuder komplett HR-service genom skapande och hantering av ärenden för snabb och intuitiv lösning Workday Journeys skapar personliga upplevelser för att guida anställda i viktiga situationer STOCKHOLM, Sverige, July 02, 2020 (GLOBE NEWSWIRE) -- Workday Inc. (NASDAQ: WDAY), ledande inom företagsmolnapplikationer för ekonomi och HR, lanserar två nya maskininlärningslösningar inom HR. Workday Help ger intuitiv ärendehantering och Workday Journeys skräddarsydd, individanpassad guidning för anställda i kritiska ögonblick. Applikationerna är de senaste tillskotten inom Workday People Experience där Workday lyfter personalupplevelsen och förenklar arbetet genom maskininlärning. Lösningarna hjälper arbetsgivare att engagera och stötta sina anställda samtidigt som arbetet blir mer personligt och produktivt. Förutom Workday People Experience lanseras även Workday People Analytics, en analysbaserad applikation som identifierar risker och möjligheter inom arbetsgrupper. Informationen ger

Workday People Anaytics levererar automatiserade lösningar för att hjälpa företag att optimera sin arbetskraft i en föränderlig värld2.7.2020 10:00:10 CESTPressemelding

Maskininlärning och augmented analytics ger insikt i och identifierar möjligheter att hjälpa företag att ta sig starkare ur krisen STOCKHOLM, Sverige, July 02, 2020 (GLOBE NEWSWIRE) -- Workday Inc. (NASDAQ: WDAY), ledande inom företagsmolnapplikationer för ekonomi och HR, lanserar Workday People Analytics – en analysbaserad applikation som identifierar risker och möjligheter inom arbetsgrupper och presenterar dessa insikter i ett lättförståeligt story-format. Informationen ger HR- och företagsledare möjlighet att nå starkare resultat – snabbare – genom att fatta bättre beslut gällande sina anställda. Workdays kunder, av vilka mer än 65 procent är Fortune 50-bolag, kan använda Workday People Analytics tillsammans med Workday Human Capital Management (HCM) för att upprätthålla kontinuitet inom företaget och hantera de utmaningar som uppstått i samband med den rådande pandemin. Förutom Workday People Analytics lanseras två lösningar för Workday People Experience som ytterligare hjälper or

Zane Kotāne has been elected as a member of the Management Board of JSC Olainfarm2.7.2020 09:46:00 CESTPress release

Today, the Supervisory Council of JSC Olainfarm has elected Zane Kotāne as a member of the Management Board, who will oversee financial matters. She has significant professional experience in management, finance and governance processes in both listed and state and private companies. “We are pleased that such a high-level specialist is joining the Management Board of Olainfarm. Zane Kotāne has significant experience in the management of both Latvian and international companies. She has in-depth knowledge in areas important to the company, such as financial analysis and planning, attracting investments from the European Union institutions and private investors, as well as internal audits. On behalf of the entire council, we wish her success,” emphasizes Gundars Bērziņš, Chairman of the Supervisory Council of JSC Olainfarm. “It is with great pleasure that I join Olainfarm's international management team and extensive staff to be able to turn a new page in the growth story of Olainfarm to

Publishing of Valmet's Half Year Financial Review January – June 2020 on July 23, 20202.7.2020 09:00:00 CESTPress release

Valmet Oyj’s press release on July 2, 2020 at 10:00 a.m. EET Valmet's Half Year Financial Review for January – June 2020 will be published on Thursday, July 23, 2020 at approximately 3:00 p.m. Finnish time (EET). The stock exchange release and presentation material in English and in Finnish will be available at that time on Valmet's website at www.valmet.com/investors. News conference for analysts, investors and media Valmet will arrange a news conference in English for investment analysts, investors, and media on Thursday, July 23, 2020 at 4:00 p.m. Finnish time (EET). The news conference will be held at Valmet Head Office in Keilaniemi, Keilasatama 5, 02150 Espoo, Finland. President and CEO Pasi Laine and CFO Kari Saarinen will be presenting at the news conference. Webcast The news conference can also be followed through a live webcast at www.valmet.com/webcasts. The live webcast starts at 4:00 p.m. (EET) and a recording of the webcast will be available shortly after the event at the

Cargotec’s January-June 2020 half year financial report to be published on Friday, 17 July 20202.7.2020 08:30:00 CESTPress release

CARGOTEC CORPORATION, PRESS RELEASE, 2 JULY 2020 AT 9.30 AM (EEST) Cargotec’s January-June 2020 half year financial report to be published on Friday, 17 July 2020 Cargotec Corporation will publish its January-June 2020 half year financial report on Friday, 17 July 2020 at approximately 2.00 p.m. EEST. The report will be available at www.cargotec.com after publication. A live international telephone conference for analysts, investors and media, will be arranged on the publishing day at 3:00 p.m. EEST. The event will be held in English. The report will be presented by CEO Mika Vehviläinen and Executive Vice President, CFO Mikko Puolakka. The presentation material will be available at www.cargotec.com by the latest 2:30 p.m. EEST. The telephone conference, during which questions may be presented, can be accessed by registering here. The registration opens 15 minutes prior to the event. The event conferencing system will call the participant on the phone number provided and place the parti

Stolt-Nielsen Limited Reports Unaudited Results For the Second Quarter and First Half of 20202.7.2020 08:25:00 CESTPress release

LONDON, July 2, 2020 – Stolt-Nielsen Limited (Oslo Børs: SNI) today reported unaudited results for the second quarter ended May 31, 2020. The Company reported a second-quarter net profit attributable to shareholders of $3.6 million, with revenue of $503.5 million, compared with a net loss attributable to shareholders of $20.0 million, with revenue of $497.1 million, in the first quarter of 2020. The net loss attributable to shareholders for the first six months was $16.3 million, with revenue of $1,000.5 million, compared with a net profit attributable to shareholders of $11.5 million, with revenue of $1,018.4 million, in the first half of 2019. Highlights for the second quarter of 2020, compared with the first quarter of 2020, were: Net profit from continuing operations amounted to $12.3 million in the second quarter, up from a loss of $19.3 million in the first quarter of 2020.Stolt Tankers reported an operating profit of $20.0 million, up from $4.7 million, mainly reflecting a $12.2